Online Inquiry

For Research Use Only. Not For Clinical Use.

Contact Us
  • Email:

Advances in the Development of Neurotoxicity Test Models

A cornerstone of modern neurotoxicology is the testing models. In this regard, considerable efforts have been made to develop robust, high-throughput, and precise neurotoxicity testing models. Creative Biolabs delves into the recent advances in the establishment of these models. Our researchers and scientists have been at the forefront of developing novel and sophisticated models for neurotoxicity testing.

Services What We Do Advantages
Neurotoxicity Screening Service Based on our extensive experience in stem cell and genome editing technologies, we can provide new neurotoxicity screening services for CNS drug discovery. We offer a range of iPSC-derived neuronal lineage cells for your project, and we can also reprogram and differentiate iPSC cells from your samples. The general screening process consists of a 3-step process that includes generation of cell lines from iPSCs, differentiation of neural cells, and disease modeling and neurotoxicity screening. For your specific needs, we can also customize the program.
  • Highly repeatable to increase the credibility of the data
  • Fast and cost-effective
  • Whole-genome profiling and immunocytochemistry (ICC) characterization
  • Differentiate into multiple cell types
  • Provide a reference for animal studies
STEMOD™ Neuroscience Ex Vivo Models Services Based on our advanced neuroscience platform, STEMOD™ neuroscience ex vivo models can be generated from cells, transgenic mice, aged rats and mice. For different research purposes, we can provide services including but not limited to: custom neural differentiation services, custom brain spheroids, custom brain organoid services, custom CNS disease modeling services, blood-brain barrier models.
  • Simple and rapid to perform
  • The reduction of the high costs of research in vivo
  • Precision and accessibility
  • Control of the extracellular environment
  • Greater mechanical stability
STEMOD™ Advanced Drug Discovery Service We develop integrated technology platforms to provide one-stop CNS drug discovery services, including studies on BBB transport and distribution in the brain.
  • Advanced technology
  • Quality facilities
  • Professional experts

Progress in In Vivo Neurotoxicity Testing

Traditionally, rodents have been the preferred species for in vivo neurotoxicity testing due to their close physiological similarity to humans. However, rodents fall short in time and cost-effectiveness, urging researchers to look for alternative in vivo models. Zebrafish have emerged as promising candidates.

  • With a fully sequenced genome and striking genetic similarity to humans, zebrafish offer an exceptional model.
  • Zebrafish embryos are particularly advantageous due to their transparency, rapid external development, and significant numbers produced in each clutch.
  • It allows researchers to monitor and quantify neurotoxic effects in real time, using live imaging techniques.
  • Zebrafish in vivo models are amenable to high-throughput screening, facilitating the rapid identification of neurotoxic substances.

In Vitro Advances in Neurotoxicity Testing

Due to the ethical restrictions and practical limitations of in vivo testing, in vitro models have gained traction, promising rapid and cost-efficient results. These models have been designed to assess the cellular and molecular mechanisms underlying neurotoxicity.

Models Examples Advantages
3D Cell Culture Models
  • More accurately represent the in vivo cellular environment
  • Form complex neural networks and promote cell-to-cell interactions
  • Study neurodevelopmental processes in a controlled environment
iPSC-Derived Models
  • Provide a consistent and reproducible source of cells
  • Study individual differences in drug response
  • Create diverse neuronal populations
  • Investigate genetic factors influencing susceptibility to neurotoxicity
Microfluidic Platforms
  • Blood-brain barrier-on-a-chip
  • Neuronal-microglial co-cultures
  • Replicate more accurately the physiological conditions of the brain
  • Model dynamic interactions between the nervous system and the circulatory system
  • Study neurotoxicity in the context of the functional blood-brain barrier
  • Improve the sensitivity of neurotoxicity testing
  • Study of the inflammatory response associated with neurotoxic injury

In addition, a number of technological advances have complemented experimental work in neurotoxicity testing. These techniques further improve the accuracy and efficiency of in vitro models.

  • To meet the growing demand for rapid and cost-effective neurotoxicity testing, the integration of high-throughput screening (HTS) technology into their in vitro models allows for the simultaneous evaluation of multiple compounds.
  • Develop multi-parametric assays that utilize advanced imaging and analytical techniques to assess various aspects of neurotoxicity. These assays simultaneously measure parameters such as cell viability, neurite growth, synaptic function, and inflammatory response.
  • Automation has been incorporated into the analytical process with the implementation of automated imaging systems and data analysis algorithms that have streamlined the process and significantly reduced the time required for data interpretation.

In Silico Models for Computational Neurotoxicity Testing

Complementing these biological models, remarkable advancements have been made in computational neurotoxicity testing. In silico models, built on vast databases of neurotoxicants and robust machine learning algorithms, can now predict the neurotoxic potential of untested substances swiftly and accurately. From simple quantitative structure-activity relationship (QSAR) models to more complex deep learning systems, computational models are continually becoming more sophisticated and precise.

Future Trends in Neurotoxicity Test Models

Future trends in neurotoxicity testing are directed towards increasing the relevance and predictability of these models to human physiology, reducing animal usage, and exploring higher-throughput techniques.

  • There is great promise in the integration of organ-on-a-chip technology with human-derived organoids and iPSCs. These microengineered devices can emulate physiological responses to drugs or toxins within a meticulously controlled microenvironment, mirroring the human body more precisely than conventional models.
  • Sophisticated AI algorithms and machine learning will play a key role in deciphering high-content screening results and data analysis. Omics-approaches including genomics, proteomics, and metabolomics will enhance our understanding of molecular mechanisms underlying neurotoxicity.

The future of neurotoxicity testing will likely involve more realistic in vitro systems mimicking complex 3D neuronal connections and diversity, high-throughput applications, the use of nanotechnologies, and more sophisticated computational models.Moreover, more predictive and improved models for chronic neurotoxicities, neurodevelopmental disorders, and neurodegenerative diseases are urgently needed. Better understanding neurotoxicity and its mechanisms requires comprehensive experimental approaches, innovative technologies, and multidisciplinary collaborations among scientists in toxicology, neuroscience, molecular biology, pharmacology, and computer science.

Adopting a combined approach, integrating in vitro, in vivo, and in silico methods, holds the future for neurotoxicity testing. Such complementary use promises to streamline the CNS drug discovery process and expedite the development of safer and more effective therapeutics.

Creative Biolabs continues to lead the way in neurotoxicity testing by utilizing emerging technologies to further refine and enhance neurotoxicity testing models.

For Research Use Only. Not For Clinical Use.